Hypoglycemia and antihyperglycemic treatment in adult MODY patients - a systematic review of literature

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000118" target="_blank" >RIV/00064173:_____/19:N0000118 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/19:43919128 RIV/00216208:11130/19:10401876 RIV/00064203:_____/19:10401876

Výsledek na webu

<a href="https://doi.org/10.1016/j.diabres.2019.107914" target="_blank" >https://doi.org/10.1016/j.diabres.2019.107914</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.diabres.2019.107914" target="_blank" >10.1016/j.diabres.2019.107914</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hypoglycemia and antihyperglycemic treatment in adult MODY patients - a systematic review of literature

Popis výsledku v původním jazyce

Maturity onset diabetes of the young (MODY) is a heterogeneous group of diseases caused by a single mutation in one of the 14 genes involved in the regulation of glucose homeostasis. GCK, HNF1A, and HNF4A genes are among the most common genes affected. Expression of these genes in the key organs for defense against hypoglycemia and their participation in counter-regulation to hypoglycemia may potentially put individuals with a heterozygous mutation in these genes at increased risk for hypoglycemia. In HNF4A-MODY and HNF1A-MODY patients, normal or even increased insulin sensitivity together with glucose-independent mechanism of action of the first-line therapy - sulphonylurea derivatives - often leads to hypoglycemia, even at the much lower dose used in type 2 diabetes. This review aims to analyze clinical studies and case reports concerning hypoglycemia associated with antihyperglycemic treatment in adult MODY patients.

Název v anglickém jazyce

Hypoglycemia and antihyperglycemic treatment in adult MODY patients - a systematic review of literature

Popis výsledku anglicky

Maturity onset diabetes of the young (MODY) is a heterogeneous group of diseases caused by a single mutation in one of the 14 genes involved in the regulation of glucose homeostasis. GCK, HNF1A, and HNF4A genes are among the most common genes affected. Expression of these genes in the key organs for defense against hypoglycemia and their participation in counter-regulation to hypoglycemia may potentially put individuals with a heterozygous mutation in these genes at increased risk for hypoglycemia. In HNF4A-MODY and HNF1A-MODY patients, normal or even increased insulin sensitivity together with glucose-independent mechanism of action of the first-line therapy - sulphonylurea derivatives - often leads to hypoglycemia, even at the much lower dose used in type 2 diabetes. This review aims to analyze clinical studies and case reports concerning hypoglycemia associated with antihyperglycemic treatment in adult MODY patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes Research and Clinical Practice

ISSN

0168-8227

e-ISSN

1872-8227

Svazek periodika

158

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

9

Strana od-do

Article 107914

Kód UT WoS článku

000501999600017

EID výsledku v databázi Scopus

2-s2.0-85075305580